Evotec (München) GmbH

https://www.evotec.com

KINAXO is a spin-off from the Max Planck Institute of Biochemistry in Martinsried, initiated by Prof. Dr. Axel Ullrich and Dr. Henrik Daub as well as Garching Innovation GmbH, the technology transfer center of the Max Planck Society. KINAXO supports pharmaceutical and biotech companies in the development and optimization of so-called spectrum-specific kinase inhibitors. With the KinaTorTM technology, KINAXO has accessed an innovative proprietary platform that can be used for efficient and directed improvement of a drug lead's therapeutic characteristics *

	Start	2014-09-16 renamed before
	Group	Evotec (Group)
	Predecessor	Kinaxo Biotechnologies GmbH
	Industry	drug discovery services
	Industry 2	KinAffinity® kinase inhibitor profiling services
	Person	Jenne, Andreas (RSP Systems 201805– CEO before NEO New Oncology + Blackfield + Kinaxo)

	Region	Martinsried
	Country	Germany
	Street	19a Am Klopferspitz
	City	82152 Martinsried
	Tel	+49-89-4524465-0
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2011-06-01)

		* Document for »About Section«:

		Record changed: 2024-12-29

Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x200px

More documents for Evotec (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com